Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE

•This study describes the inclusions in early clinical trials of ACC patients.•Cohort of 27 patients enroled in 30 early clinical trials.•Median PFS was 3.02 months with a disease control rate of 61%.•Median GMI was 1.32, with a significantly prolonged PFS in 52% as compared to previous line.•ACC patients may benefit from inclusion in early clinical trials in second line.